Recently, I came across information online about the Critical Path Institute (C-Path), a non-profit based in Tucson, Arizona. Founded in 2005, C-Path connects scientists from the FDA, academia and industry with the hopes of collaboration.
A public-private partnership, C-Path aims to accelerate the pace of research. It also promotes systems to reduce the costs of medical product development through new data standards, measurement standards, and methods standards that aid in the scientific evaluation of the efficacy and safety of new therapies.
Collaboration and reducing costs is so important because is failure rate of testing new drug therapies is an astounding 95 percent.
That’s a sobering number.
C-Path and GAAIN Partnership
From its website: “C-Path orchestrates the sharing of data, expertise and knowledge among industry, regulatory authorities, government, patient advocacy groups and academia in the pre-competitive space to generate the evidence needed to improve the drug development pathway.”
C-Path hopes to make research less complicated, and it may be making some pretty impressive progress.
Just a few days ago, C-Path made a big announcement regarding Alzheimer’s disease. The news involves a partnership in a massive Global Alzheimer’s Research Data-Sharing Network called GAAIN.
GAAIN is best described as an open-access resource that provides the world’s foremost Alzheimer’s scientists with rapid access to big-data research. Included is information from 21 data partners and more than 320,000 research participants. This information portal is hosted by the University of Southern California (USC) and it’s Laboratory of Neuro Imaging at the Keck School of Medicine.
“Data sharing is the cornerstone for enabling advances in regulatory sciences that provide a gateway to new innovative treatments for patients with neurodegenerative disorders with impaired cognition and function,” said Stephen Arneric, PhD, Executive Director of CAMD.
“Our goal is to create drug development tools in collaboration with our members and regulators to accelerate the delivery of treatments that prevent or slow these diseases, so patients can maintain independence and health-related quality of life,” Arneric said.
You can read all of the details about GAAIN at this link on the C-Path website.
Reading this news gave me a glimmer of hope. It’s not an immediate solution to the Alzheimer’s puzzle, but it may be one big step toward finding a cure or effective treatments for this terrible disease.